Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | TKT | P29401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16716586 | 0.82 | KDM4E (0.36) | AGBL2NR1H2NR1H3KDM4E | |
| SCHEMBL18975041 | 0.81 | KIF11 (0.39) | KIF11 | |
| SCHEMBL22728415 | 0.81 | NR1H2 (0.35) | AGBL2NR1H2NR1H3 | |
| SCHEMBL335735 | 0.79 | KIF11 (0.31) | HSD17B10KIF11 | |
| SCHEMBL21503558 | 0.79 | NPC1 (0.35) | AGBL2NR1H2NR1H3KDM4EHSD17B10 | |
| SCHEMBL20696509 | 0.79 | ALDH1A1 (0.37) | — | |
| SCHEMBL18975037 | 0.79 | NPC1 (0.43) | FYNHSD17B10 | |
| SCHEMBL21503556 | 0.78 | NR1H2 (0.32) | AGBL2NR1H2NR1H3PPARD | |
| SCHEMBL2712954 | 0.78 | PTGS2 (0.39) | AGBL2NR1H2NR1H3KDM4EHSD17B10 | |
| SCHEMBL30391692 | 0.78 | PTGS2 (0.39) | AGBL2NR1H2NR1H3KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| CN-102105473-B | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| CN-102105473-A | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2011-06-22 | — | — | CN | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306089-A1 | COMPOUNDS | SDHA, NQO1, SDHB | AGBL2 2894/4885CYP2A6 238/4885NR1H2 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.